Heartsciences INC 8-K filings

HeartSciences Inc. received a notification from Nasdaq regarding non-compliance with the minimum stockholders' equity requirement for continued listing.

HeartSciences reports progress towards FDA submissions and advancements in AI-ECG technology for Q3 Fiscal Year 2025.

HeartSciences Inc. granted stock options to its executive officers and non-employee directors on January 16, 2025, as part of its compensation and incentive plans.

HeartSciences Inc. has withdrawn its registration statement for a proposed public offering of common stock to explore alternative financing options.

HeartSciences reports progress in AI-ECG technology development and provides a business update for the second quarter of fiscal year 2025, ending October 31, 2024.

HeartSciences Inc. held its Annual Meeting of Stockholders on November 7, 2024, where shareholders ratified the appointment of Haskell & White LLP as the company's auditor and approved the adjournment proposal.

Heart Test Laboratories, Inc. has officially changed its name to HeartSciences Inc., effective October 11, 2024, following shareholder approval.

Heart Test Laboratories, Inc. has officially changed its corporate name to HeartSciences Inc., following shareholder approval.

Heart Test Laboratories reported its first quarter fiscal 2025 results, highlighting progress in its AI-ECG technology and securing additional financing.

Heart Test Laboratories has entered into a note purchase agreement with Streeterville Capital, securing $2.51 million in funding to be used for general working capital.

Heart Test Laboratories has extended the maturity date of its loan with Front Range Ventures to September 30, 2025, and amended the loan agreement to include new interest payment terms.

HeartSciences reports its fiscal year 2024 results, highlighting progress in its AI-ECG technology and platform development, and a strong balance sheet.

Heart Test Laboratories, Inc. has regained compliance with Nasdaq's minimum bid price requirement, avoiding a scheduled hearing and maintaining its listing.

Heart Test Laboratories has received a stay on its delisting from Nasdaq pending a hearing, following a reverse stock split aimed at regaining compliance.

Heart Test Laboratories clarifies that only its common stock will trade on a split-adjusted basis following a reverse stock split, while warrant adjustments will be made equitably.

Heart Test Laboratories has completed a 1-for-100 reverse stock split and adjusted its warrants, with trading on a split-adjusted basis to begin on May 17, 2024.

Heart Test Laboratories, Inc. is facing potential delisting from the Nasdaq Capital Market due to low stock price and has implemented a 1-for-100 reverse stock split to regain compliance.

Heart Test Laboratories, Inc. d/b/a HeartSciences announced a strategic shift towards a broad portfolio of AI-ECG algorithms and a significantly improved financial position in its third quarter fiscal 2024 results.

Heart Test Laboratories successfully amended its Certificate of Formation to reduce the quorum requirement for shareholder meetings at a reconvened annual meeting on February 15, 2024.

Heart Test Laboratories has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement, extending the deadline to July 29, 2024.

Heart Test Laboratories' pro forma balance sheet indicates a significant increase in stockholders' equity to over $10 million following recent stock offerings and debt conversions.

Heart Test Laboratories, Inc. successfully passed several key proposals at its 2024 Annual Meeting, but adjourned the meeting to secure additional votes for a quorum reduction proposal.